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Purpose: The purpose of the study was to assess the relationship between patient-reported 
severity of dry eye disease (DED), quality of life (QoL), presence of diabetic retinopathy 
(DR) and length of disease duration in people with type 1 diabetes mellitus (DM1) and type 2 
diabetes mellitus (DM2).
Patients and methods: A survey of 152 people (110 with and 42 without diabetes). All 
participants completed the Ocular Surface Disease Index (OSDI) and Dry Eye-related Quality 
of Life Score (DEQS) questionnaires.
Results: Forty-four percent of all diabetic subjects reported dry eye symptoms, compared 
to 29% in the control group. Patients with DM2 reported dry eye symptoms more frequently 
than those with DM1 (55% and 27% respectively, P=0.001). Dry eye severity was linked to a 
significant deterioration in QoL in both types of diabetes (DM1, r=0.609 and P=0.036; DM2, 
r=0.417 and P=0.011). Irrespective of DR, the presence of DED was significantly higher in 
DM2 compared to DM1 (with DR, P=0.011; without DR, P=0.018).
Conclusion: Dry eye symptoms are associated with reduced QoL and are more common in 
people with DM2 than in DM1, irrespective of DR status. Routine clinical screening for severe 
DED could potentially allow for a timely and more effective treatment and could contribute to 
mitigating the dry eye-associated reduction in QoL in those with DM2.
Keywords: ocular surface, dry eye, symptoms, retinopathy
Introduction
Diabetes is one of the leading causes of morbidity and mortality worldwide.1 In 2017, 
425 million people were diagnosed with diabetes globally, and this figure is expected to 
exceed 629 million by 2045.2 People with diabetes are more prone to suffer from dry eye 
disease (DED; either aqueous-deficient or evaporative) than those without diabetes.3–7 
DED is a multifactorial disease associated with aging and autoimmune disease.8 
Signs and symptoms may vary from patient to patient and include ocular discomfort, 
pain, blurred vision, corneal ulcers, and in severe cases, blindness.8,9 DED also has 
a significant impact on patient quality of life (QoL), including physical, social, and 
psychological; negatively affecting daily activities10–13 and workplace productivity.13,14 
DED has a substantial economic impact as a result of these QoL effects.13
As DED has been reported as a symptom-based disease,15 we assessed the severity 
of patient-reported DED using the Ocular Surface Disease Index (OSDI) and the 
Dry Eye-related Quality of Life Score (DEQS) questionnaires. Previous studies have 
suggested there is an association between diabetes and DED,3–6,16 with a recent study 
suggesting a correlation between the prevalence of DED and glycemic control.17 
To date, however, there have been no studies investigating the effects of diabetes-
associated DED on patient QoL.
Correspondence: Md Kaosar 
Yazdani-ibn-Taz
Monno Medical College and hospital, 
Monno City, gilanda 1840, Manikganj 
Dhaka, Bangladesh
Tel +880 170 538 7134
email myazda200@caledonian.ac.uk 
Journal name: Clinical Ophthalmology
Article Designation: Original Research
Year: 2019
Volume: 13
Running head verso: Yazdani-Ibn-Taz et al




























































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





The aims of this study were to assess patient-reported 
severity of DED and its impact on QoL in people with type 1 
and type 2 diabetes mellitus (DM1 and DM2), compared to 
healthy controls. A secondary aim was to investigate the pos-
sible association of DED and QoL with age, gender, duration 
of diabetes, presence of diabetic retinopathy (DR) status, 
diabetic maculopathy, diabetic neuropathy, and glycemic 
control (HbA1c).
Patients and methods
study design and participants
This study was approved by the Ethics committee of Glasgow 
Caledonian University (no HLS/LS/A15/047) and was con-
ducted in accordance with Declaration of Helsinki guidelines. 
Written informed consent was obtained from each subject 
involved in this project after a full explanation of the proce-
dures involved. The study comprised 110 participants with 
diabetes (DM1, n=45; DM2, n=65) attending the Diabetes 
Clinic (University Hospital Ayr) and 42 controls. Patients 
with Graves’ disease, connective tissue disorders, and 
chronic kidney disease were excluded. Patient demographic 
characteristics (age and sex) and related medical information 
(ie, presence of DR, duration of diabetes, use of medications, 
etc) were obtained from SCI-Diabetes.
Data collection
Patient-reported dry eye symptoms and 
health-related Qol
Each participant was asked to complete two questionnaires: 
1) the OSDI (Allergan, Inc, Irvine, CA, USA) for DED 
severity assessment,18 and 2) the DEQS (Santen Pharmaceu-
tical Co. Ltd. and Dry Eye Society in Japan), to allow for 
assessment of QoL. Both the questionnaires provide a score 
of 0–100, with higher scores indicating greater symptom 
severity and greater reduction of QoL, respectively.18,19
OsDi
OSDI is the most commonly used DED questionnaire for 
clinical trials, measuring symptom frequency and severity. 
The OSDI questionnaire consists of 12 questions grouped into 
three sections: ocular symptoms, vision-related function, and 
environmental factors.18 It is designed to assess the patients’ 
symptoms18,20 and the impact of these symptoms on day-to-
day life.18 This questionnaire has been accepted for use in US 
Food and Drug Administration clinical trials for DED.18,21,22 
The OSDI represents DED symptoms of the previous 7 days 
and yields scores ranging from 0 (least symptoms) to 100 
(worst symptoms). Each item is graded on a scale of 0–4, 
where 0 indicates none of the time; 1, some of the time; 2, 
half of the time; and 4, all of the time.18,23,24 DED severity 
is determined based on the score calculated with the OSDI 
formula, that is, the sum of the score is multiplied by 25 and 
then is divided by the number of questions answered.23 A 
score of 12 is considered the cutoff for normal, 13–22 for 
mild, 23–32 for moderate, and $33 for severe DED.18,23,24
DeQs
The DEQS is a self-evaluating method, which provides 
assessment of the effect of the symptoms of DED on QoL 
in general, including the mental health of the patient. The 
DEQS includes 15 questions and two sub-categories: impact 
on daily life and bothersome ocular symptoms. Each ques-
tionnaire was scored on a 4-point Likert scale ranging from 
1 to 4, with a larger number indicating a greater burden. 
The final score is calculated using the DEQS formula, that 
is, multiplying the sum of the score by 25 and then dividing 
the total by the number of questions answered. The summary 
score for the DEQS ranges from 0 to 100, where the higher 
the score, the greater the disability. This questionnaire has 
been validated and is often used in clinical trials.19
statistical analyses
IBM SPSS software (Version 24; IBM Corporation, Armonk, 
NY, USA) was used for all analyses. Descriptive statistics 
were generated. Frequency tables were used to assess DED 
severity. Pearson’s chi-squared test, Spearman’s correlation (r) 
test were used to determine any differences and association 
between variables. Scatter plots were generated to assess the 




The mean duration of diabetes was significantly longer for 
those with DM1 (22±13 years) than with DM2 (12±7 years; 
P,0.001). All subjects with diabetes had a significantly 
higher mean age (55±16 years) than the controls (43±9 years; 
P,0.001). Although there was a significant difference in the 
male:female ratio between DM1 and controls (P=0.002), 
the presence of more female participants did not influence 
DED presence in the controls (P=0.554). The demographic 
characteristics of the two diabetic groups and the controls 
are shown in Table 1.
Participant-reported DeD
DeD in the diabetes groups (OsDi)
DED symptoms were reported by 44% (n=48) of all 
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was significantly higher in those with DM2 compared to 
DM1 (P=0.001). Just over one quarter of all DM1 subjects 
reported DED symptoms (27%; n=12), while 55% of DM2 
participants (n=36) reported DED symptoms (Table 2). 
Among DM1 participants with DED symptoms, five had 
mild, three had moderate, and four had severe DED symp-
toms (Table 2). Nearly half of those with DM2 (n=17) 
reported mild symptoms, eight had moderate, and eleven 
reported severe symptoms of DED. In the control group, 
12 described DED symptoms, with eight having mild symp-
toms, two with moderate symptoms, and two with severe 
symptoms. For the mean OSDI score in patients with DED, 
no significant difference was found between DM2 and DM1 
(P=0.198). Mean OSDI scores in patients with DED were, 
however, significantly higher in both DM2 (P=0.001) and 
DM1 (P=0.03), compared to controls.
Participant-reported Qol in DeD (DeQs)
There was a positive association between DED severity 
(measured by OSDI) and impact on QoL (measured by 
DEQS) in participants with diabetes (r=0.487; P,0.001). 
That is, DED severity of both DM1 (r=0.609; P=0.036) 
and DM2 (r=0.417; P=0.011) were linked to a significant 
deterioration in QoL (Figures 1 and 2). For the participants 
with DM1 and DM2, DED equally affected their QoL; no 
significant difference was observed between the groups 
(P=0.346). For the mean DEQS score in those with DED, 
no significant difference was found between DM2 and DM1 
(P=0.198). Likewise, in comparison with controls, the mean 
DEQS score in those with DED was not different for either 
DM2 (P=0.131) or DM1 (P=0.834) (Table 2).
While more severe DED symptoms had a significantly 
worse impact on QoL in DM2 patients (P=0.013), no such 
impact was observed in those with DM1 (P=0.053). A signifi-
cant positive correlation was also found between DEQS and 
HbA1c in DM2 (r=0.492; P=0.002), indicating that higher 
HbA1c levels were associated with worse QoL, specifically 
in DM2. By contrast, no significant association was found 
between DEQS and HbA1c in DM1 (Table 3).
DeD and Dr
For those with DM1 and DR, 28% (n=8) had DED, of 
whom 37.5% (n=3) reported mild, 25% (n=2) moderate, 
and 37.5% (n=3) reported severe DED symptoms. In those 
with DM2 and DR, 63% (n=22) suffered DED, of whom 
45.5% (n=10) reported mild, 23% (n=5) moderate, and 32% 
(n=7) reported severe DED symptoms. DED presence was 
significantly higher in DM2 with DR (63%) than for DM1 
with DR (28%; P=0.011). Among DM1 participants without 
DR, 25% (n=4) reported DED, of whom 50% (n=2) had 
mild, 25% (n=1) had moderate, and 25% (n=1) had severe 
symptoms. In DM2 without DR, 46.7% (n=14) had DED, of 
whom 50% (n=7) had mild, 21% (n=3) had moderate, and 
29% (n=4) had severe symptoms. For people without DR, 
DED presence was significantly higher in DM2 compared 
to DM1 (P=0.018).
DeD, diabetes complications, duration of diabetes, 
and other health indicators
There was no association between DR, diabetic maculopathy, 
diabetic neuropathy, and DED. Similarly, no significant 
association was found between DED and age, gender, or 
glycemic control (P.0.05; Tables 4 and 5). For control 
subjects, DED was not associated with either age (P=0.676) 
or gender (P=0.554).
Discussion
Patients with diabetes are known to have an increased 
prevalence of DED compared to healthy controls,25–27 and 
the impact of DED on patients’ QoL has been reported as 
similar to that observed for patients with angina, hip frac-
tures, or those undergoing dialysis.28 Although the prevalence 








Mean ± sD 47±17 61±13 43±9
sex
Male 30 44 13
Female 15 21 29
Abbreviations: DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus.
Table 2 Participant-reported DeD symptoms severity vs Qol 
scores in study groups and controls












Mild 5 17 8
Moderate 3 8 2
severe 4 11 2
OsDi score in those with DeD
Mean ± sD 26±16 33±23 21±8
DeQs score in those with DeD
Mean ± sD 20±16 28±23 22±15
Abbreviations: DeD, dry eye disease; DeQs, Dry eye-related Quality of life 
score; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; OsDi, Ocular 
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and association of DED with diabetes has been reported 
previously,3–6,25–27,29 this study demonstrated differences in the 
proportion of diabetic patients affected by DED and its impact 
on patients’ QoL, depending on diabetes type. The overall 
DED presence in the current study (44%) was comparable 
to previous generic diabetes studies, that is, studies where 
no distinction was made between DM1 and DM2 patients. 
These include Fuerst et al,3 Hom and De Land,26 and Ogundo 
et al27 who reported DED prevalence among diabetics of 52%, 
52.9% and 49.8%, respectively, but was higher than that the 
value of 20.6% reported by Kaiserman et al.5 Our findings 
differ from that of Kaiserman et al5 as they determined DED 
by ocular lubrication use; this difference might be because 
1) patients from relatively poorer economic backgrounds are 
less likely to purchase ocular lubricants (despite their need), 
or 2) through lack of awareness of using ocular lubricants, 
due to decreased corneal sensitivity that commonly occurs 
in those with diabetes.5
In the current study, there was a significant association 
between DED and DM2 (P=0.003) as well as DED and 
DM1 (P=0.003), which corresponds with earlier studies for 
DM217,30,31 and for DM1.16 Of particular interest was our 
????????????? ?? ?? ?? ??????
????
?? ?? ??
Figure 1 a scatter plot showing the association of DeD and Qol in people with DM1.
Note: There was a statistically significant correlation between OSDI and DEQS (Spearman’s rho, r=0.609; P=0.036).
Abbreviations: DeD, dry eye disease; DeQs, Dry eye-related Quality of life score; DM1, type 1 diabetes mellitus; OsDi, Ocular surface Disease index; Qol, quality of life.
Figure 2 a scatter plot showing the association of DeD and Qol in people with DM2.
Note: There was a statistically significant correlation between OSDI and DEQS (Spearman’s rho, r=0.417; P=0.011).
Abbreviations: DeD, dry eye disease; DeQs, Dry eye-related Quality of life score; DM2, type 2 diabetes mellitus; OsDi, Ocular surface Disease index; Qol, quality of life.
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finding that there was a higher DED prevalence in those with 
DM2 (56% by OSDI) than for DM1 (27%). In our study, the 
prevalence of DM2-associated DED was comparable to other 
reports on DM2 cohorts, such as Manaviat et al30 (54.3%; 
determined by tear break-up time [TBUT] and Schirmer test) 
and Rathnakumar et al31 (53%, TBUT and Schirmer test), but 
was higher than that reported by Najafi et al4,32 (27.7%, as deter-
mined by tear osmolarity). This difference between our findings 
and Najafi et al4 might be due to the fact that in long-standing 
diabetes, patients with higher tear osmolarity often experience 
fewer dry eye symptoms.3 Other studies have shown that DM2 
is significantly associated with DED.33,34 The only other study 
we could find that compared DED in both the diabetes types 
reported an overall DED prevalence of 52.8% across both the 
types, with 57% in DM1 and 70% in DM2 patients.16 Between 
studies, the differences in DED presence for DM2 may be due 
to the DED definition used, the study populations, and the 
diagnostic methods, that is, objective vs subjective means. 
It is unclear why there was a significant difference in DED 
presence between the two types. The possibility exists that it 
reflects their different underlying pathophysiologies.
Nevertheless, we have shown that DED is an important 
clinical entity, which can be found in a large proportion of 
people with DM2. Interestingly, in our study, DED pres-
ence in DM1 (27%) was similar to the controls (29%). 
Furthermore, our study provides novel information by 
comparing DED presence and severity in relation to QoL 
in both DM1 and DM2, using patient-reported outcomes. A 
strong positive association was observed (P,0.001) between 
DED severity and impact on QoL of the respondents in DM 
(both types), irrespective of their DR status.
We did not observe a correlation between DED and other 
demographic data, such as age, sex, duration of diabetes, or 
HbA1c. There have been previous reports that suggested 
that DED is more prevalent in the elderly,7,29,35–37 female 
sex,4,7,23,27,35–37 higher HbA1c levels,5,17,29 diabetes duration,3,30 
DR,3,4 diabetic maculopathy,4,30 and DN.38 However, other 
studies similarly reported that DED has no correlation with 
age and gender,3,30 HBA1c value,3,30,39 diabetes duration,4 
or DN.4 The lack of correlation may be because of reduced 
corneal sensitivity with increased severity of DR4,40 or DN41,42 
or increasing age36,43–45 and reduced corneal sensitivity cannot 
be measured by subjective tests.46 Moreover, HbA1c only 
reflects blood glucose level over the past 3 months, while 
loss of corneal sensitivity can occur as a result of long-term 
hyperglycemia.3,40 Therefore, HbA1c levels might not be 
associated with decreased corneal sensation, which can 
impact the perception of DED symptoms.3
This study is not without limitations. First, using subjec-
tive (patient-reported) methods in diagnosing DED could 
have created a biased result, due to inter-observer differ-
ences in reporting. In this study, there are several reasons 
for and benefits in using the OSDI and DEQS question-
naires. The OSDI is regarded as a valid and reliable tool 
for measuring DED presence and severity in research or 
clinical practice. Most importantly, it has defined cutoff 
values that can effectively evaluate DED presence and 
its severity.3,13,15,18,24 It should be noted that clinical DED 
diagnosis is regarded as difficult at the best of times, due 
to discrepancies between signs and symptoms.47–49 Further-
more, relatively objective tests such as TBUT, Schirmer 
test, and lissamine green staining have shown a poor 








age −0.249 0.436 −0.079 0.648
Duration 0.295 0.352 0.165 0.345
hba1c 0.424 0.194 0.492 0.002a
Note: aP-value of ,0.05 is significant.
Abbreviations: DeQs, Dry eye-related Quality of life score; DM1, type 1 diabetes 
mellitus; DM2, type 2 diabetes mellitus.
Table 4 association (Pearson chi-squared test) between DeD 
and tested variables in DM1 and DM2
Variables DM1 (P-value) DM2 (P-value)
gender 0.475 0.338
Diabetic retinopathy 0.851 0.124
Diabetic maculopathy 0.787 0.415
DeD severity 0.001** 0.001**
Diabetic neuropathy 0.692 0.618
Note: **P,0.01.
Abbreviations: DeD, dry eye disease; DM1, type 1 diabetes mellitus; DM2, type 2 
diabetes mellitus.








age 0.232 0.467 −0.024 0.887
Duration 0.258 0.419 −0.197 0.258
hba1c 0.291 0.385 0.184 0.283
Abbreviations: DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; 
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correlation with clinical signs.50,51 Previous population-based 
studies have assessed the prevalence of DED by symptoms 
alone50–52 and DED symptom assessment has been commonly 
reported as the foremost diagnostic tool by both optometrists 
and ophthalmologists.52–54 A recent cross-sectional survey of 
optometrists and ophthalmologists in New Zealand reported 
that 90% of respondents ranked patient symptoms as the 
most useful diagnostic tool for DED.55 The DEQS is also a 
validated and reliable method used in routine clinical prac-
tice to assess the various effects of DED on the patient’s 
day-to-day activities.19
Second, this was a cross-sectional study and not a longi-
tudinal one; it was therefore difficult to determine whether 
DED preceded or followed the diagnosis of diabetes. Thus, it 
was not possible to state that DED was solely a consequence 
of diabetes. Other risk factors, such as use of medications 
(which may cause tear hyposecretion, such as antihistamines, 
tricyclic antidepressants, or oral contraceptives), contact lens 
usage, and laser therapy, should be considered as exclusion 
criteria for future studies. Other limitations of this study 
were age and sex differences between study participants 
and controls and the relatively small patient sample cohorts. 
This is likely to be addressed in future studies. Despite these 
limitations, there is strong evidence that the study demon-
strated a significant association between DED and DM as 
well as DED and both DM1 and DM2, while DED severity 
was linked to a significantly reduced QoL for both diabetes 
types. We also report that the severity of dry eye in those with 
or without DR is significantly higher in DM2 than in DM1.
To date, few studies have directly compared DED in 
DM1 and DM2, which have different underlying etio-
pathogeneses. Nor have there been any reports on the effects 
that diabetes-associated DED may have on overall patient 
QoL. Despite the fact that DED is much more prevalent in 
diabetes, it is often overlooked in this patient demographic 
due to the more pressing concerns of DR monitoring. As DED 
is more prevalent in DM2, adding DED assessment to DR 
screening could be beneficial in people with DM2. This 
additional screening might incur an extra cost which need 
to be evaluated in future studies. However, medical cost 
for DED treatment can outweigh the loss of productivity 
and may produce economic benefits.14 Not all patients with 
diabetic eye disease will have DED, but those with DED 
tend to experience lower QoL. Thus, improving the QoL of 
the patients (through relieving the symptoms, improvement 
of visual acuity, restoration of ocular surface and tear film, 
and correction of underlying defects) should be the primary 
aim for DED treatment as it has a wider physical, social, 
psychological, and economic impact on both individuals and 
society as a whole.9,13,14
Conclusion
Clinical examination for DED could be beneficial in people 
with diabetes and should be routinely included when assess-
ing patients for diabetic eye disease, especially for those 
with DM2.
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